The bulk of the discussion at this year’s ACCESS 2025 conference fell into four buckets: (1) the effect of the Trump administration’s tariffs on the active pharmaceutical ingredient (API) supply chain, (2) the magnitude of the potential lost opportunity for biosimilars that are not developed (or the “biosimilar void”), (3) the effect of the Department … Continue reading Addressing Rapidly Changing Biosimilar Dynamics at Access 2025